Medical Equipment

Direct Oral Anticoagulants (DOACs) Device Market Developments And Opportunities Across 2026–2030

April 10, 2026April 15, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Much Growth In Market Value Is Expected For The Direct Oral Anticoagulants (DOACs) Device Market Between 2026 And 2030?

The direct oral anticoagulants (doacs) device market size has demonstrated significant expansion in recent years. It is anticipated to increase from $32.8 billion in 2025 to $35.69 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 8.8%. This historical growth can be attributed to factors like the constrained availability of doac monitoring devices, the established dependence on hospital-based coagulation tests, the escalating prevalence of atrial fibrillation and thrombotic disorders, the wider adoption of oral anticoagulant therapies, and a heightened focus on patient safety and anticoagulation monitoring.

The direct oral anticoagulants (doacs) device market size is anticipated to experience substantial growth in the coming years. It is projected to expand to $49.48 billion by 2030, with a compound annual growth rate (CAGR) of 8.5%. The growth during this forecast period can be attributed to advancements in portable and point-of-care devices, the integration with digital health platforms and cloud-based monitoring, a rising adoption of personalized anticoagulation management, the expansion of homecare and specialty clinic services, and increasing regulatory approvals for novel monitoring systems. Key trends anticipated in the forecast period include the growing adoption of point-of-care doac monitoring devices, increasing use of factor xa and direct thrombin inhibitor monitoring, rising awareness of stroke and thromboembolism prevention, the expansion of homecare and ambulatory monitoring solutions, and an enhanced focus on accuracy, sensitivity, and rapid testing capabilities.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=27281&type=smp

What Key Factors Are Affecting The Direct Oral Anticoagulants (DOACs) Device Market Demand?

The anticipated expansion of the direct oral anticoagulants (DOACs) device market is primarily fueled by the rising occurrence of cardiovascular disorders. These disorders encompass various ailments affecting the heart and blood vessels, frequently resulting in complications like heart attacks, strokes, or other circulatory problems. A key factor in the surge of cardiovascular disorders is the growing adoption of sedentary lifestyles, which contribute to weight gain, increased blood pressure, and the gradual deterioration of cardiovascular health. Direct oral anticoagulants (DOACs) play a crucial role in managing these conditions by significantly reducing the risk of stroke and blood clot formation in individuals suffering from atrial fibrillation, providing dependable anticoagulation without requiring routine blood tests. For example, data from October 2024 released by the Centers for Disease Control and Prevention, a US-based government agency, indicated that in 2023, cardiovascular disease was responsible for 919,032 lives, representing one in every three deaths. Coronary heart disease remained the most common type of heart ailment, and notably, approximately one in six deaths due to cardiovascular diseases occurred among adults younger than 65 years. Consequently, the escalating incidence of cardiovascular disorders is a significant catalyst for the expansion of the direct oral anticoagulants (DOACs) device market.

How Is Segmentation Applied In The Direct Oral Anticoagulants (DOACs) Device Market Segment Analysis?

The direct oral anticoagulants (doacs) device market covered in this report is segmented –

1) By Product: Factor Xa Inhibitors, Direct Thrombin Inhibitors

2) By Disease: Atrial Fibrillation, Deep Vein Thrombosis, Pulmonary Embolism, Heart Attacks, Post-Surgical Thromboprophylaxis, Other Diseases

3) By Application: Stroke Prevention, Venous Thromboembolism Prevention, Treatment Of Acute Thrombotic Events, Long-Term Prophylaxis, Other Applications

4) By End User: Hospitals, Ambulatory Surgical Centers, Specialty Clinics, Homecare Settings, Other End Users

Subsegments:

1) By Factor Xa Inhibitors: Rivaroxaban Monitoring Devices, Apixaban Monitoring Devices, Edoxaban Monitoring Devices, Betrixaban Monitoring Devices

2) By Direct Thrombin Inhibitors: Dabigatran Etexilate, Dabigatran Mesylate

What Trends Are Influencing Changes In The Direct Oral Anticoagulants (DOACs) Device Market?

Leading companies within the direct oral anticoagulants (DOACs) device market are concentrating on creating sophisticated solutions, such as automated coagulation assays, aimed at enhancing the precision, effectiveness, and uniformity of direct oral anticoagulant level tracking in clinical settings. These automated coagulation assays represent machine-conducted laboratory analyses that determine the rate of blood clotting, assisting in the diagnosis of bleeding or clotting conditions. An illustration of this is Roche Holding AG, a Switzerland-based pharmaceutical company, which introduced three novel coagulation tests in February 2024, specifically tailored for Factor Xa inhibitors. These offerings improve clinicians’ capacity to precisely assess the anticoagulation state of individuals on direct Factor Xa inhibitors like rivaroxaban and apixaban. They support clinical judgments by accurately quantifying the anti-Xa activity of apixaban, edoxaban, rivaroxaban, and heparin during crucial situations such as bleeding episodes, overdoses, or impending surgeries. Leveraging Roche’s reagent cassette technology on cobas t analyzers, these automated diagnostics yield superior results, reduce the need for manual intervention, and optimize the efficiency of laboratory operations.

Who Are The Companies Participating In The Direct Oral Anticoagulants (DOACs) Device Market Environment?

Major companies operating in the direct oral anticoagulants (doacs) device market are Pfizer Inc., Roche Diagnostics Corporation, Bristol-Myers Squibb Company, Siemens Healthcare GmbH, Becton Dickinson And Company, Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Limited, Daiichi Sankyo Co. Ltd, Sysmex Corporation, Dr. Reddy’s Laboratories Limited, Werfen S.A., Alembic Pharmaceuticals Limited, Diagnostica Stago SAS, Helena Laboratories Corporation, iLine Microsystems S.L., Technoclone GmbH, Anthos Therapeutics Inc., FLoBio LLC, Perosphere Technologies Inc., DOASENSE GmbH.

Get The Full Direct Oral Anticoagulants (DOACs) Device Market Report:

https://www.thebusinessresearchcompany.com/report/direct-oral-anticoagulants-doacs-device-global-market-report

Which Region Leads The Direct Oral Anticoagulants (DOACs) Device Market In Terms Of Market Share?

North America was the largest region in the direct oral anticoagulants (DOACs) device market in 2025. The regions covered in the direct oral anticoagulants (doacs) device market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Direct Oral Anticoagulants (DOACs) Device Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/customise?id=27281&type=smp

Browse Through More Reports Similar to the Global Direct Oral Anticoagulants (DOACs) Device Market 2026, By The Business Research Company

Machine Learning Market Report 2026

https://www.thebusinessresearchcompany.com/report/machine-learning-global-market-report

Financial Analytics Market Report 2026

https://www.thebusinessresearchcompany.com/report/financial-analytics-global-market-report

Machine Learning Ml In The Pharmaceutical Industry Market Report 2026

https://www.thebusinessresearchcompany.com/report/machine-learning-ml-in-the-pharmaceutical-industry-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795